There is a lower incidence of pneumonitis in PD-1/PD-L1 inhibitor monotherapy than in concurrent or sequential chemotherapy (29), radiotherapy (30) or immunotherapy (3, 17, 27, 31). Here, PDCD1 is linked to pneumonitis.